TREATMENT-FREE RESPONSE USING BRAZILIAN IMATINIB COPIES AS FIRST LINE -RESULTS FROM TWO PROSPECTIVE CLINICAL TRIALS
Lido
1498
Vezesque se leu este artigo
613
Total PDF
885
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 10 | 36 | 18 | 54 |
| 2025 9 | 45 | 25 | 70 |
| 2025 8 | 36 | 15 | 51 |
| 2025 7 | 42 | 24 | 66 |
| 2025 6 | 44 | 20 | 64 |
| 2025 5 | 53 | 11 | 64 |
| 2025 4 | 39 | 11 | 50 |
| 2025 3 | 54 | 17 | 71 |
| 2025 2 | 38 | 13 | 51 |
| 2025 1 | 30 | 23 | 53 |
| 2024 12 | 25 | 10 | 35 |
| 2024 11 | 29 | 17 | 46 |
| 2024 10 | 32 | 31 | 63 |
| 2024 9 | 33 | 26 | 59 |
| 2024 8 | 35 | 25 | 60 |
| 2024 7 | 32 | 31 | 63 |
| 2024 6 | 31 | 19 | 50 |
| 2024 5 | 39 | 22 | 61 |
| 2024 4 | 33 | 27 | 60 |
| 2024 3 | 22 | 17 | 39 |
| 2024 2 | 17 | 24 | 41 |
| 2024 1 | 19 | 12 | 31 |
| 2023 12 | 11 | 15 | 26 |
| 2023 11 | 15 | 21 | 36 |
| 2023 10 | 12 | 25 | 37 |
| 2023 9 | 10 | 21 | 31 |
| 2023 8 | 9 | 14 | 23 |
| 2023 7 | 8 | 3 | 11 |
| 2023 6 | 9 | 12 | 21 |
| 2023 5 | 12 | 6 | 18 |
| 2023 4 | 6 | 6 | 12 |
| 2023 3 | 3 | 6 | 9 |
| 2023 2 | 6 | 11 | 17 |
| 2023 1 | 5 | 3 | 8 |
| 2022 12 | 8 | 18 | 26 |
| 2022 11 | 4 | 9 | 13 |
| 2022 10 | 3 | 5 | 8 |
Mostrar tudo
